A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

May 21, 2012

Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated with Chemotherapy

Read more about Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated with Chemotherapy
May 18, 2012

Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012

Read more about Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012
May 16, 2012

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First Line Advanced RCC

- Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment -

Read more about AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First Line Advanced RCC
May 10, 2012

Issuance of Stock Acquisition Rights for Stock Option Scheme under Stock-Linked Compensation Plan

Read more about Issuance of Stock Acquisition Rights for Stock Option Scheme under Stock-Linked Compensation Plan
May 7, 2012

Astellas Announces Favorable Ruling in Patent Infringement Case

Read more about Astellas Announces Favorable Ruling in Patent Infringement Case
Apr 26, 2012

Astellas Nominates Directors

Read more about Astellas Nominates Directors
Apr 25, 2012

Astellas and Drais Partner To Develop Astellas Compound through Telsar

InterWest Partners, Sutter Hill Ventures and Astellas Venture Management Invest $14 Million into Telsar to Advance Compound

Read more about Astellas and Drais Partner To Develop Astellas Compound through Telsar
Apr 5, 2012

FDA Advisory Committee Recommends Approval of Mirabegron – Investigational Overactive Bladder Treatment from Astellas

Read more about FDA Advisory Committee Recommends Approval of Mirabegron – Investigational Overactive Bladder Treatment from Astellas
Apr 2, 2012

Astellas CSR Website Renewed

-- Content Regarding Access to Health Added -

Read more about Astellas CSR Website Renewed
Mar 30, 2012

Astellas Pharma Obtains Approval in Japan for Treating Hyperphosphatemiawith Kiklin® Capsules

Tokyo, March 30, 2012 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that Kiklin® Capsules (development code: ASP1585, generic...

Read more about Astellas Pharma Obtains Approval in Japan for Treating Hyperphosphatemiawith Kiklin® Capsules

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts